PPA
TTNP

Parametric Portfolio Associates’s Titan Pharmaceuticals TTNP Stock Holding History

Parametric Portfolio Associates’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed -$44K – 4033
2017
Q1 		$44K Hold
4
– – ﹤0.01% 3748
2016
Q4 		$52K Buy
4
+1
+33% +$16.8K ﹤0.01% 3738
2016
Q3 		$62K Buy
+3
New +$58.3K ﹤0.01% 3722

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $9.05B AUM 13.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $75.9M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Parametric Portfolio Associates's TTNP Position: Q2 2017 in Review

Parametric Portfolio Associates sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 4 shares — an estimated $44K sold.

Parametric Portfolio Associates first reported a position in TTNP in Q3 2016 and held it in 3 quarters. The position peaked at $62K in Q3 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

  • Parametric Portfolio Associates reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Parametric Portfolio Associates sold 4 Titan Pharmaceuticals shares in Q2 2017, an estimated $44K.
  • Parametric Portfolio Associates first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Parametric Portfolio Associates's Titan Pharmaceuticals position peaked at $62K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on Parametric Portfolio Associates's 13F filing for Q2 2017, filed 11 Aug 2017.